Orthobiologics: body-material care for your sore joint

What does the amount of wear tell me?

An X-ray shows the gap between the bones. Cartilage normally cushions that gap. A smaller gap can mean the cartilage has worn thin. The doctor also looks at bone shape and checks how the joint moves, because an X-ray can’t measure how much you hurt or show every sore tendon beside it.

Mild or middle wear means the gap has narrowed but isn’t gone. That doesn’t make every treatment sensible. You may still discuss exercise, medicine, or blood-based care before surgery. Bone-on-bone wear calls for a frank surgery talk. No body-material treatment can rebuild a worn joint.

The X-ray grades wear. Your daily limits show how much it matters.

Could blood-based care fit this joint?

Maybe. You won’t know until the clinician checks whether the joint itself or a nearby tendon hurts. You’ll be asked which motions hurt and whether swelling comes and goes. Bring old films if you have them.

QC Kinetix provides regenerative treatment options; that broad term covers care made from blood, marrow, fat, or donor tissue. Clinics shorten platelet-rich plasma to PRP. Blood comes from your arm, then a machine spins it and gathers platelets, tiny blood pieces that help form clots. The platelet-rich part is placed at the sore area. Concentrated PRP keeps a larger share of those blood parts. The clinic may discuss it when your exam finds joint or tendon soreness and the X-ray doesn’t show end-stage wear.

You’ll know the reason before you spend money or effort.

What does "PRP vs stem cell" leave out?

It leaves out what’s taken from you. PRP needs a blood draw. Marrow-based care takes marrow from the pelvis. Fat-based care needs a fat-removal procedure. Those services can take more time and cost more. A higher price doesn’t prove better relief.

Ask what will be taken, where it will be placed, and how the next few days may feel. Ask when you’ll judge the result. Get the full price too. You need an answer for what comes next if your soreness doesn’t change.

Compare the work, risk, cost, and likely relief.

Sources

1. The ESSKA-ORBIT European consensus on blood-derived orthobiologics graded 28 question-statement sets; only 9 of 28 had high-level scientific support. Three statements reached grade A: that there is enough preclinical and clinical evidence to support PRP use in knee OA; that clinical evidence shows effectiveness in MILD TO MODERATE knee OA (KL grade 3 or lower); and that PRP provides a longer effect than the short-term effect of corticosteroid with a safer profile. The panel regarded PRP as a valid and possible first-line injectable option for KL grades 1-3.

   Laver L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma).. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12077.

2. The companion ESSKA-ORBIT consensus on cell-based therapy (77 experts, 22 countries, 27 statements) found only 5 of 27 statements reached recommendation level A or B; 22 were rated C or D. It concluded that cell-based therapy shows clinical benefit in pain and function up to 12 months for KL grades 1-3 with some benefit in selected KL 4, but that because of limited high-quality studies and NO clear superiority over other injectables it should be considered a SECOND-LINE option, after other non-operative treatment fails.

   de Girolamo L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A formal ESSKA-ORBIT consensus. Part 2-Cell-based therapy.. Knee Surgery, Sports Traumatology, Arthroscopy, 2025. DOI: 10.1002/ksa.70001.

3. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

4. A meta-analysis of 27 Level I studies (1,042 PRP, 226 BMAC, 1,128 HA patients) found significantly better post-injection WOMAC, VAS and subjective IKDC scores for BOTH PRP and BMAC compared with hyaluronic acid - and NO significant difference between PRP and BMAC on any outcome score. This is the clearest published statement that the two most-marketed orthobiologics perform the same as each other in the knee.

   Belk JW, et al. — Patients With Knee Osteoarthritis Who Receive Platelet-Rich Plasma or Bone Marrow Aspirate Concentrate Injections Have Better Outcomes Than Patients Who Receive Hyaluronic Acid: Systematic Review and Meta-analysis.. Arthroscopy, 2023. DOI: 10.1016/j.arthro.2023.03.001.

5. A randomized controlled trial compared a SINGLE ultrasound-guided injection of leukocyte-rich PRP (n=30) with micro-fragmented adipose tissue (n=28) in KL 1-4 knee OA. Both groups improved clinically meaningfully from baseline, and there was no significant difference in the primary outcome (KOOS-Pain at 6 months: 80.38 vs 81.61; P=.67) or in any other score - despite MFAT requiring a lipoaspiration procedure and PRP requiring only a blood draw.

   Baria M, et al. — Platelet-Rich Plasma Versus Microfragmented Adipose Tissue for Knee Osteoarthritis: A Randomized Controlled Trial.. Orthopaedic Journal of Sports Medicine, 2022. DOI: 10.1177/23259671221120678.

6. A network meta-analysis of 11 RCTs (1,353 patients) with HIP osteoarthritis found that at 2-4 and 6 months NO intervention - corticosteroid, hyaluronic acid or PRP - significantly outperformed intra-articular saline placebo for either pain or function, while all interventions including placebo produced improvement exceeding the minimal clinically important difference from baseline. Evidence from the knee does not transfer to the hip.

   Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

7. A meta-analysis of 11 RCTs (730 patients) with lateral epicondylitis found the timing reverses the answer: corticosteroid was significantly BETTER than PRP in the short term (under 2 months: VAS mean difference 0.93 favouring steroid; DASH 10.23 favouring steroid), the two did not differ at 2-6 months, and PRP was significantly better at 6 months or more (VAS -2.18; DASH -8.13; Mayo Elbow +16.53).

   Xu Y, et al. — Platelet-Rich Plasma Has Better Results for Long-term Functional Improvement and Pain Relief for Lateral Epicondylitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.. American Journal of Sports Medicine, 2024. DOI: 10.1177/03635465231213087.

8. A meta-analysis of 27 RCTs (1,779 patients) across rotator cuff injury, lateral epicondylitis, plantar fasciitis and tenosynovitis found no PRP advantage at one month anywhere, and in some tendons corticosteroid was better early; PRP overtook corticosteroid at 3 months for rotator cuff VAS and at 6 months for plantar fasciitis VAS and AOFAS and for tenosynovitis VAS.

   Ye Z, et al. — Platelet-rich plasma and corticosteroid injection for tendinopathy: a systematic review and meta-analysis.. BMC Musculoskeletal Disorders, 2025. DOI: 10.1186/s12891-025-08566-3.

9. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

10. The HIT randomized trial (198 participants) found that adding a single ultrasound-guided triamcinolone-plus-lidocaine hip injection to best current treatment improved hip pain over six months (mean difference -1.43, 95% CI -2.15 to -0.72), but that the triamcinolone arm was NOT better than ultrasound-guided lidocaine alone; benefit was concentrated in patients with ultrasound-confirmed synovitis or effusion.

    Paskins Z, et al. — Clinical effectiveness of one ultrasound guided intra-articular corticosteroid and local anaesthetic injection in addition to advice and education for hip osteoarthritis (HIT trial): single blind, parallel group, three arm, randomised controlled trial.. BMJ, 2022. DOI: 10.1136/bmj-2021-068446.

11. In a controlled cohort of 1,471 patients injected in the hip, 106 (7.2%) developed rapidly progressive idiopathic arthritis; compared with controls they were older, had narrower joint spaces and higher Croft scores before injection - so pre-injection joint severity, not the injectate or the anaesthetic, marked the at-risk group.

    Boutin RD, et al. — Rapidly progressive idiopathic arthritis of the hip: incidence and risk factors in a controlled cohort study of 1471 patients after intra-articular corticosteroid injection.. Skeletal Radiol, 2021. DOI: 10.1007/s00256-021-03815-7.

12. A 2021 JAMA review of hip and knee osteoarthritis places intra-articular steroid injections as providing SHORT-TERM pain relief within a management model whose cornerstones are exercise, weight loss if appropriate and education, complemented by topical or oral NSAIDs, with joint replacement reserved for advanced symptoms and structural damage.

    Katz JN, et al. — Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review.. JAMA, 2021. DOI: 10.1001/jama.2020.22171.

13. A clinical review of peripheral joint injections frames them as a treatment for joint-mediated pain (arthritis, tendinopathy, bursitis) that has NOT responded to conservative management, and states plainly that these injections are typically not curative - their objective is to reduce pain enough to allow physical and pharmacologic rehabilitation to work.

    Marcolina A, et al. — Peripheral Joint Injections.. Phys Med Rehabil Clin N Am, 2022. DOI: 10.1016/j.pmr.2022.01.005.